Anthera, Inc.
355 Webster, Suite H
Palo Alto
California
94301
United States
Tel: 650-322-7861
Fax: 650-327-8295
Email: ubhagat@anthera.com
24 articles about Anthera, Inc.
-
Anthera Surpasses 50% Milestone For Screening Of Patients In RESULT Phase III Clinical Study Of Sollpura In Cystic Fibrosis
9/7/2017
-
Anthera Announces Top Line Final Data From The Extension Period Of The Phase II BRIGHT-SC Study Of Blisibimod In Patients With IgA Nephropathy
8/28/2017
-
Anthera Announces RESULT Phase III Clinical Study Of Sollpura Will Be Included In The European Cystic Fibrosis Clinical Trial Network
8/14/2017
-
Anthera Announces FDA Orphan Drug Designation For Blisibimod For The Treatment Of IgA Nephropathy
8/10/2017
-
Anthera Provides Business Update and Reports 2017 Second Quarter Financial Results
8/9/2017
-
Anthera Announces Expansion Of Screening In European Sites In Phase III RESULT Clinical Study Of Sollpura
7/6/2017
-
Anthera Announces First Patient Screened In RESULT Pivotal Phase III Clinical Study Of Sollpura
5/16/2017
-
Anthera Provides Business Update And Reports 2017 First Quarter Financial Results
5/11/2017
-
Anthera Announces 1-For-8 Reverse Split Of Stock
5/1/2017
-
Anthera Announces Completion Of Dosing In The Phase II BRIGHT-SC Study Of Blisibimod In Patients With IgA Nephropathy
4/10/2017
-
Bay Area's Anthera Names a New CEO in Shakeup
12/7/2016
-
Anthera Provides Business Update And Reports 2016 Second Quarter Financial Results
8/9/2016
-
Anthera PharmaAnnounces Completion Of Dosing In CHABLIS-SC1 Phase III Clinical Study With Blisibimod
8/4/2016
-
Anthera Provides Clinical Program Updates For Blisibimod And Sollpura
6/29/2016
-
Anthera Provides Business Update And Reports 2016 First Quarter Financial Results
5/9/2016
-
Anthera Announces Appointment Of Dr. James Pennington As Interim Chief Medical Officer
3/7/2016
-
Anthera Announces Initiation Of The SOLUTION Clinical Study Of Oral Sollpura (Liprotamase) Unit-Matched Therapy Of Non-Porcine Origin In People With Cystic Fibrosis
10/2/2015
-
Anthera, Inc. Announces $3 Million Research Award From Cystic Fibrosis Foundation Therapeutics, Inc. For Development Of Sollpura - A Novel Enzyme Therapy
3/20/2015
-
Anthera, Inc. And Patheon Inc. Sign Manufacturing Agreement For Liprotamase Phase 3 Registration Trial
11/20/2014
-
Boehringer Ingelheim Corporation Passes on Anthera, Inc.'s CV Antibody Option
11/13/2014